Base case, scenario, and PSAs
| Strategy . | Cost, $ (USD) . | Incremental cost, $ (USD) . | Effectiveness, QALYs . | Incremental effectiveness, QALYs . |
|---|---|---|---|---|
| Base-case analysis | ||||
| Standard care | 13 070 300 | 25.1 | ||
| Emicizumab | 13 122 500 | 52 200 | 25.6 | 0.52 |
| ICER, $99 900 per QALY (95% CI, 84 000-120 000) | ||||
| Scenario analysis, 50% emicizumab dose reduction | ||||
| Standard care | 6 648 800 | 25.1 | ||
| Emicizumab | 6 659 100 | 10 300 | 25.6 | 0.52 |
| ICER, $19 600 per QALY (95% CI, 12 000-29 000) | ||||
| Scenario analysis, standard half-life prophylaxis after ICH and age 1 year | ||||
| Standard care | 9 780 700 | 23.4 | ||
| Emicizumab | 9 832 500 | 51 800 | 23.9 | 0.52 |
| ICER, $99 700 per QALY (95% CI, 83 000-121 000) | ||||
| Scenario analysis, emicizumab vial wastage in age 0- to 1-year period | ||||
| Standard care | 13 070 400 | 25.1 | ||
| Emicizumab | 13 136 400 | 66 000 | 25.6 | 0.52 |
| ICER, $126 300 per QALY (95% CI, 107 000-151 000) | ||||
| Strategy . | Cost, $ (USD) . | Incremental cost, $ (USD) . | Effectiveness, QALYs . | Incremental effectiveness, QALYs . |
|---|---|---|---|---|
| Base-case analysis | ||||
| Standard care | 13 070 300 | 25.1 | ||
| Emicizumab | 13 122 500 | 52 200 | 25.6 | 0.52 |
| ICER, $99 900 per QALY (95% CI, 84 000-120 000) | ||||
| Scenario analysis, 50% emicizumab dose reduction | ||||
| Standard care | 6 648 800 | 25.1 | ||
| Emicizumab | 6 659 100 | 10 300 | 25.6 | 0.52 |
| ICER, $19 600 per QALY (95% CI, 12 000-29 000) | ||||
| Scenario analysis, standard half-life prophylaxis after ICH and age 1 year | ||||
| Standard care | 9 780 700 | 23.4 | ||
| Emicizumab | 9 832 500 | 51 800 | 23.9 | 0.52 |
| ICER, $99 700 per QALY (95% CI, 83 000-121 000) | ||||
| Scenario analysis, emicizumab vial wastage in age 0- to 1-year period | ||||
| Standard care | 13 070 400 | 25.1 | ||
| Emicizumab | 13 136 400 | 66 000 | 25.6 | 0.52 |
| ICER, $126 300 per QALY (95% CI, 107 000-151 000) | ||||